UK medicines regulator gears up for bigger role post-Brexit

A new five-year plan from the Medicines and Healthcare products Regulatory Agency (MHRA), the UK’s medicines regulator, sets out the group's aim to “ensure a smooth EU exit under any scenario.”

The  report comes with less than a year to go until so-called ‘Brexit’ is scheduled to occur, and the UK will leave the economic and political union of 28 nations.

Politicians are currently negotiating the details of a ‘transition period’ of just under two years, during which time the UK is likely to continue under many of the current trading and customs arrangements.